Molecular analysis of curcumin-induced polarization of murine RAW264.7 macrophages

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 6, 2014, Pages 544-552

  Chen, Fangyuan ^a   Guo, Ning ^a   Cao, Guofen ^a   Zhou, Juan ^a   Yuan, Zuyi ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Curcumin; Macrophages polarization; Murine RAW264.7 macrophages

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; CURCUMIN; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANALYSIS; ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; CELL POLARITY; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; CELL POLARITY; CELL SURVIVAL; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; MACROPHAGES; MICE;

EID: 84902248441     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000079     Document Type: Article

References (50)

1. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis. Circ J. 2010;74:213-220.
2. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl. 2005;6:21-29.
3. Pello OM, Silvestre C, De Pizzol M, et al. A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology. 2011;216:1172-1176.
4. Laskin DL. Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. Chem Res Toxicol. 2009;22:1376-1385.
5. Mantovani A, Garlanda C, Locati M. Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol. 2009;29:1419-1423.
6. Lacy-Hulbert A, Moore KJ. Designer macrophages: oxidative metabolism fuels inflammation repair. Cell Metab. 2006;4:7-8.
7. Biswas SK, Mantovani A. Orchestration of metabolism by macrophages. Cell Metab. 2012;15:432-437.
8. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11:723-737.
9. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011;106:763-771.
10. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795.
11. Feinberg MW, Cao Z, Wara AK, et al. Kruppel-like factor 4 is a mediator of proinflammatory signaling in macrophages. J Biol Chem. 2005;280: 38247-38258.
12. Klco JM, Kulkarni S, Kreisel FH, et al. Immunohistochemical analysis of monocytic leukemias: usefulness of CD14 and Kruppel-like factor 4, a novel monocyte marker. Am J Clin Pathol. 2011;135:720-730.
13. Liao X, Sharma N, Kapadia F, et al. Krüppel-like factor 4 regulates macrophage polarization. J Clin Invest. 2011;121:2736-2749.
14. Alder JK, Georgantas III RW, Hildreth RL, et al. Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. J Immunol. 2008;180:5645-5652.
15. Sharma N, Lu Y, Zhou G, et al. Myeloid Krüppel-like factor 4 deficiency augments atherogenesis in ApoE2/2 mice?brief report. Arterioscler Thromb Vasc Biol. 2012;32:2836-2838.
16. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab. 2007;6:137-143.
17. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophagespecific PPARg controls alternative activation and improves insulin resistance. Nature. 2007;447:1116-1120.
18. Liu GYH. Modulation of macrophage activation and programming in immunity. J Cell Physiol. 2013;228:502-512.
19. Szanto A, Balint BL, Nagy ZS, et al. STAT6 transcription factor is a facilitator of the nuclear receptor PPARgamma-regulated gene expression in macrophages and dendritic cells. Immunity. 2010;33:699-712.
20. Li S, Zhou Q, He H, et al. Peroxisome proliferator-activated receptor gamma agonists induce cell cycle arrest through transcriptional regulation of Kruppel-like factor 4 (KLF4). J Biol Chem. 2013;288: 4076-4084.
21. Cekanova M, Lee SH, McEntee MF, et al. MCC-555-induced NAG-1 expression is mediated in part by KLF4. Eur J Pharmacol. 2010;637:30-37.
22. Pazienza V, Vinciguerra M, Mazzoccoli G. PPARs signaling and cancer in the gastrointestinal system. PPAR Res. 2012;2012:560846.
23. Rageul J, Mottier S, Jarry A, et al. KLF4-dependent, PPARgammainduced expression of GPA33 in colon cancer cell lines. Int J Cancer. 2009;125:2802-2809.
24. Hatcher H, Planalp R, Cho J, et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631-1652.
25. Baliga MS, Joseph N, Venkataranganna MV, et al. Curcumin, an active component of turmeric in the prevention and treatment of ulcerative colitis: preclinical and clinical observations. Food Funct. 2012;3:1109-1117.
26. Schaffer M, Schaffer PM, Zidan J, et al. Curcuma as a functional food in the control of cancer and inflammation. Curr Opin Clin Nutr Metab Care. 2011;14:588-597.
27. Shehzad A, Ha T, Subhan F, et al. New mechanisms and the antiinflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr. 2011;50:151-161.
28. Epstein J, Docena G, MacDonald TT, et al. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr. 2010;103:824-832.
29. Zhong Y, Liu T, Guo Z. Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF-kappaB pathways in rat vascular smooth muscle cells. Inflamm Res. 2012;61:61-67.
30. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606-1614.
31. Kim DC, Ku SK, Bae JS. Anticoagulant activities of curcumin and its derivative. BMB Rep. 2012;45:221-226.
32. Ejaz A, Wu D, Kwan P, et al. Curcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL mice. J Nutr. 2009; 139:919-925.
33. Coban D, Milenkovic D, Chanet A, et al. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res. 2012;56: 1270-1281.
34. Lee KH, Chow YL, Sharmili V, et al. BDMC33, a curcumin derivative suppresses inflammatory responses in macrophage-like cellular system: role of inhibition in NF-kappaB and MAPK signaling pathways. Int J Mol Sci. 2012;13:2985-3008.
35. Meng Z, Yan C, Deng Q, et al. Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-kappaB pathways. Acta Pharmacol Sin. 2013;34: 901-911.
36. Pae HO, Jeong SO, Kim HS, et al. Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS. Mol Nutr Food Res. 2008;52:1082-1091.
37. Jacob A, Wu R, Zhou M, et al. Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res. 2007;2007: 89369.
38. Hogan CM, Thatcher TH, Sapinoro RE, et al. Electrophilic PPARgamma ligands attenuate IL-1beta and silica-induced inflammatory mediator production in human lung fibroblasts via a PPARgamma-independent mechanism. PPAR Res. 2011;2011:318134.
39. Larmonier CB, Midura-Kiela MT, Ramalingam R, et al. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:503-515.
40. Kou MC, Chiou S-Y, Weng CY, et al. Curcuminoids distinctly exhibit antioxidant activities and regulate expression of scavenger receptors and heme oxygenase-1. Mol Nutr Food Res. 2013;57:1598-1610.
41. Mazzolani F, Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin Ophthalmol. 2013;7:939-945.
42. Ben P, Liu J, Lu C, et al. Curcumin promotes degradation of inducible nitric oxide synthase and suppresses its enzyme activity in RAW 264.7 cells. Int Immunopharmacol. 2011;11:179-186.
43. Siddiqui AM, Cui X, Wu R, et al. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med. 2006; 34:1874-1882.
44. Jeong SO, Oh G-S, Ha HY, et al. Dimethoxycurcumin, a synthetic curcumin analogue, induces heme oxygenase-1 expression through Nrf2 activation in RAW264.7 macrophages. J Clin Biochem Nutr. 2009;44:79-84.
45. Tao C, Xiao L, Ming H, et al. Introduction and Identification of M1/M2 phenotype of RAW264.7 cells. Mol Cardiol China. 2011;11:117-120.
46. Khallou-Laschet J, VA, Fornasa G, et al. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:e8852.
47. Jeong YI, Kim SW, Jung ID, et al. Curcumin suppresses the induction of indoleamine 2,3-dioxygenase by blocking the Janus-activated kinaseprotein kinase Cdelta-STAT1 signaling pathway in interferon-gammastimulated murine dendritic cells. J Biol Chem. 2009;284:3700-3708.
48. Wang HM, Zhao YX, Zhang S, et al. PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis. 2010;20:1189-1199.
49. Bhatt KH, Sodhi A, Chakraborty R. Peptidoglycan induced expression of peroxisome proliferator-activated receptor gamma in mouse peritoneal macrophages: role of ERK and JNK MAP kinases. Cytokine. 2012;60: 778-786.
50. Ji Y, Sun S, Xu A, et al. Activation of natural killer T cells promotes M2 macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity. J Biol Chem. 2012;287:13561-13571.